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Donor and recipient genetic 
variants in NLRP3 associate with 
early acute rejection following 
kidney transplantation
Mark C. Dessing1,*, Jesper Kers1,*, Jeffrey Damman1, Gerjan J. Navis2, Sandrine Florquin1,3 & 
Jaklien C. Leemans1
NLRP3 (NOD-like receptor family, pyrin domain containing 3) is a member of the inflammasome 
family and is of special interest in renal disease. Experimental studies have shown that Nlrp3 plays 
a significant role in the induction of renal damage and dysfunction in acute and chronic renal injury. 
However, the role of NLRP3 in human renal disease is completely unknown. From a retrospective cohort 
study, we determined in 1271 matching donor and recipient samples if several NLRP3 single nucelotide 
polymorphisms (SNPs) were associated with primary non-function (PNF), delayed graft function (DGF), 
biopsy-proven acute rejection (BPAR) and death-censored graft and patient survival. NLRP3 gain-of-
function SNP (rs35829419) in donors was associated with an increased risk of BPAR while NLRP3 loss-of-
function SNP (rs6672995) in the recipient was associated with a decreased risk of BPAR in the first year 
following renal transplantation (HR 1.91, 95% CI 1.38–2.64, P < 0.001 and HR 0.73, 95% CI 0.55–0.97, 
P = 0.03 resp.). NLRP3 SNPs in both donor and recipient were not associated with PNF, DGF, graft 
survival or patient survival. We conclude that genetic variants in the NLRP3 gene affect the risk of acute 
rejection following kidney transplantation.
Improving long-term renal allograft survival remains a major challenge and allograft longevity is affected by 
factors including donor type and age, kidney preservation method, ischemia-reperfusion injury (IRI) and occur-
rence of acute rejection1. Because the pool of living (un)related donor kidneys (LD) is limited, the majority of 
renal allografts are recovered from deceased brain dead and deceased cardiac dead donors. Unfortunately, the 
latter two groups display more IRI and inferior transplant outcome compared to LD2. IRI leads to necrosis, local 
and systemic immune activation and it contributes to delayed graft function (DGF), which in turn is associ-
ated with higher rates of acute rejection and affect graft survival. Innate immunity plays an important role in 
the mechanisms underlying IRI. Inflammasomes are innate immune sensors and monitor for signs of infection 
and tissue damage3,4. Protein-complex formation of inflammasome member NLRP3 (NOD-like receptor family, 
pyrin domain containing 3) with ASC (Apoptosis-associated Speck-like protein containing a Caspase activa-
tion and recruitment domain) and Caspase-1 leads to formation of active IL-1β , IL-18 and IL-33 and, through 
non-canonical inflammasome signalling, to a programmed form of cell death called pyroptosis3–7. NLRP3 is 
the best-characterized inflammasome and is of special interest in renal diseases. NLRP3 is able to induce an 
inflammatory response upon activation by endogenous stress ligands called damage-associated molecular pat-
terns (DAMPs), which are released following tissue injury, including IRI. In addition, NLRP3 is highly expressed 
in murine and human renal epithelial cells and leukocytes and increasing amounts of experimental data show 
that Nlrp3 deficiency prevents renal dysfunction, damage and inflammation in several murine acute and chronic 
renal disease models8–12. Genotyping of SNPs (single nucleotide polymorphisms) is frequently used to determine 
the effects of genetic variations in the context of human diseases. Determination of NLRP3 SNPs in donor and 
recipient DNA offers an unique opportunity to characterize the effects of transplant-associated NLRP3 compared 
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to the host’s infiltrating leukocyte-associated NLRP3, respectively. So far it is known that NLRP3 SNPs with a 
gain-of-function (GOF) are related to several auto-inflammatory disorders due to an enhanced inflammatory 
state in these patients13–16. Currently, it is unknown if NLRP3 SNPs are related to human renal diseases or patient 
outcome after solid organ transplantation5. Therefore, we determined NLRP3 SNPs in a large cohort of matching 
donors and recipients and investigated their association with renal allograft and patient outcomes.
Results
NLRP3 SNP distribution in donors and recipients. Baseline characteristics of donors and recipi-
ents are displayed in Table 1. In our cohort, genotypic distribution of NLRP3-related SNPs in donor and recipient 
were comparable to previous general/Caucasian population distributions (Supplementary Table S1 and 
www.ensemble.org). None of the SNPs deviated significantly from a Hardy-Weinberg equilibrium (all P > 0.46 after 
Holm-Bonferroni correction). In the combined model (A/A vs. A/a + a/a) genotype distribution of NLRP3 SNPs 
were comparable between donors and recipient and SNPs were not considered as a potential risk factor for diseases 
of the native kidneys. SNPs with minor allele frequency less than 1% were left out from further analysis (N = 3).
NLRP3 SNPs are not associated with delayed graft function, primary non-function, graft sur-
vival or patient survival. Delayed graft function (DGF) occurred in 415/1271 patients (33%) of which 
60/415 resulted in primary non-functioning (PNF) of the graft (14% of DGF, 5% of total patients). None of the 
3 NLRP3 SNPs in either donor or recipient were correlated to the occurrence of DGF or PNF (Table 2). After 
stratification by donor type (living and cadaveric), again none of the NLRP3 SNPs were significantly associated 
with DGF or PNF (Supplementary Table S2). Median overall graft survival was 5.5 years (interquartile range 
2.9–8.9 years). The overall cumulative incidence of death-censored graft failure was 215/1271 (17%) of which 
136/215 due to rejection (63% of graft failure, 11% of total). We did not observe a significant association between 
any of the NLRP3 SNPs, in either donor or recipient, with death-censored graft failure (Table 2). The cumulative 
incidence of patient mortality was 220/1271 (17%). Donor and recipient NLRP3 SNPs were not associated with 
patient survival (Table 2).
Genetic variants in NLRP3 are a risk factor for biopsy-proven acute rejection. The overall cumu-
lative incidence of biopsy-proven acute rejection (BPAR) was 34% (433/1271). The NLRP3 SNP rs35829419 
(GOF) in the donor (A/a + a/a) was significantly associated with an increased risk for BPAR in the complete 
follow-up (HR 1.48, 95% CI 1.12–1.96, P = 0.006; Table 3 and Fig. 1), which was observed in cadaveric, but not 
in living donors after stratification for donor type (cadaveric donor HR 1.58, 95% CI 1.16–2.16, P = 0.004 vs. 
living donor HR 1.16, 95% CI 0.62–2.18, P = 0.64). NLRP3 SNP rs6672995 (LOF) in the recipient (A/a + a/a) was 
significantly associated with a decreased risk for BPAR in the complete follow-up (HR 0.72, 95% CI 0.58–0.91, 
P = 0.005; Table 3 and Fig. 1) which was observed in cadaveric, but not living donor after stratification for 
donor type (cadaveric donor HR 0.69, 95% CI 0.53–0.90, P = 0.005 vs. living donor HR 0.83, 95% CI 0.53–1.30, 
P = 0.42). From the Kaplan-Meier curves we could observe that BPAR occurred particularly within the first year 
after transplantation (Fig. 1). Therefore, we also stratified the patients in those who experienced a BPAR within 
the first 12 months after transplantation (early BPAR, N = 393 events) and those who experienced their first 
episode of BPAR later than 12 months after transplantation (late BPAR, N = 40 events). NLRP3 SNP rs35829419 
in the donor was significantly associated with early, but not late BPAR (early BPAR HR 1.54, 95% CI 1.15–2.05, 
P = 0.003 vs. late BPAR HR 0.82, 95% CI 0.25–2.67, P = 0.74; Table 3). Similarly, NLRP3 SNP rs6672995 in the 
recipient was associated with early, but not late BPAR (early BPAR HR 0.68, 95% CI 0.54–0.87, P = 0.002 vs. late 
BPAR HR 1.16, 95% CI 0.60–2.25, P = 0.66; Table 3). Little differences in donor type distribution were observed 
for rs6672995 SNP allele combinations in recipients (Table S3).
Donor rs35829419 and recipient rs6672995 NLRP3 variants are independently associated with 
biopsy-proven acute rejection. Next, we created multivariate models adjusting for parameters that are 
known risk factors for BPAR from the literature, including donor and recipient age, recipient gender, type of 
donation (all without missing values), cold ischemia time (0.4% missing values), number of HLA mismatches 
(0.6% missing), previous transplantation (0.1% missing), pre-transplant panel reactive antibodies (3.0% missing), 
pre-transplant dialysis time (3.3% missing) and the use of induction therapy with interleukin-2-receptor antag-
onists (no missing values). In separate multivariate regression models, donor NLRP3 SNP rs35829419 (HR 1.37, 
95% CI 1.01–1.87, P = 0.04; Table 4) and recipient NLRP3 SNP rs6672995 (HR 0.71, 95% CI 0.55–0.92, P = 0.01; 
Table 4) were independently associated with BPAR on complete follow-up. When we created a multivariate regres-
sion model that included both the donor rs35829419 and recipient rs6672995 NLRP3 SNPs in one analysis, both 
variants were contributors to the occurrence of BPAR (HR 1.34, 95% CI 0.99–1.83, P = 0.06 and HR 0.71, 95% CI 
0.55–0.93, P = 0.01, respectively; light-gray area Table 4). When we performed mutliple imputations and recal-
culated the multivariable model including both SNPs, similar results were obtained (HR 1.38, 95% CI 1.04–1.83, 
P = 0.02 and HR 0.75, 95% CI 0.60–0.94, P = 0.01, respectively). By 10x internal cross-validation, these results 
were calculated to be 9.9% over-optimistic. Comparable results were obtained when we only investigated the 
cumulative incidence of BPAR within the first 12 months after transplantation (donor rs35829419 HR 1.42, 95% 
CI 1.04–1.94, P = 0.03 and recipient rs6672995 HR 0.67, 95% CI 0.51–0.89, P = 0.005; light-gray area Table 4). 
Again, when we performed mutliple imputations and recalculated the multivariable model including both SNPs, 
similar results were obtained (HR 1.41, 95% CI 1.06–1.89, P = 0.02 and HR 0.71, 95% CI 0.56–0.91, P = 0.006, 
respectively). By 10x internal cross-validation, these results were calculated to be 10.5% over-optimistic. In 
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conclusion, these results indicate that NLRP3 SNPs rs35829419 (GOF) in the donor and rs6672995 (LOF) 
in the recipient both contribute to the risk of BPAR, and more specifically to those episodes of BPAR that occur 
within the first year after transplantation.
Variable
Whole study group 
N = 1271
Donor characteristics
 Age (mean years ± SE) 44.4 ± 14.4
 Male N (%) 645 (51%)
Donortype N (%)
  Living donor 282 (22%)
  Cadaveric donor (DBD + DCD) 989 (78%)
Donor cause of death N (%)
  CVA 549 (43%)
  Trauma 305 (24%)
  Other 135 (11%)
  Unknown 282 (22%)
Recipient characteristics
 Age (mean years ± SE) 47.9 ± 13.4
 Male N (%) 739 (58%)
Primary kidney disease N (%)
  Glomerulonephritis 271 (21%)
  Adult polycyctis kidney disease 167 (13%)
  Renal vascular disease 124 (10%)
  IgA Nephropathy 98 (8%)
  Pyelonephritis 148 (12%)
  Diabetic 51 (4%)
  Chronic 168 (13%)
  Other 244 (19%)
Initial immunosuppression N (%)
  Corticosteroids 1201 (95%)
  Mycophenolic acid 907 (71%)
  Cyclosporin 1085 (85%)
  Azithioprin 72 (6%)
  Tacrolimus 97 (8%)
  Sirolimus 38 (3%)
Induction therapy
  ATG 103 (8%)
  Anti-CD3 moab 19 (2%)
  Interleukin-2 RA 199 (16%)
Transplant number N (%)
  First 1142 (90%)
  Second 128 (10%)
Transplant characteristics
Cold ischemia time (mean hours ± SE)
  Living donor 2.7 ± 1.9
  Cadaveric donor 20.7 ± 6.5
 HLA no. of 0 mismatches N (%) 241/1050 (23%)
Cause of graft loss N = 212 (%)
  Rejection 132 (62%)
  Technical problems 37 (17%)
  Primary recurrent disease 16 (8%)
  Primary non-viable 12 (6%)
  Infection 3 (1%)
  Other 12 (6%)
Table 1.  Baseline characteristics of the whole study group. DBD = deceased brain death, DCD = deceased 
cardiac death, CVA = cerebrovasculair accident, ATG = antithymocyte globulin, moab = monoclonal antibody, 
RA = receptor antagonist, SE = standard error.
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Discussion
The NLRP3 inflammasone is of special interest in renal diseases because of its expression pattern in murine and 
human kidneys and its detrimental role in experimental models of acute and chronic renal injury8–12. Thus far, 
nothing is known about the role of NLRP3 in human renal diseases or solid organ transplantation. Determination 
of NLRP3 SNPs in donor and recipient DNA offers a unique opportunity to characterize the differential effects 
of transplant- and the host’s leukocyte-associated NLRP3 inflammasome. We quantified several NLRP3 SNPs in 
a large cohort consisting of > 1200 matched donors and recipients. We found that the NLRP3 gain-of-function 
SNP rs35829419 in donors associated with an increased risk of acute rejection, whereas on the contrary that the 
NLRP3 loss-of-function SNP rs6672995 in recipients associated with a reduced risk of rejection, particularly 
those episodes that occurred within the first year after transplantation.
NLRP3 SNPs became of particular interest in human disease because of their association and causal 
role in several autoinflammatory disorders. Gain-of-function mutations in the NLRP3 gene (R260W and 
Q705K) lead to enhanced basal IL-1β production and are linked to Muckle-Well syndrome, familial cold 
autoinflammatory syndrome and chronic infantile neurologic cutaneous and articular syndrome13–16. 
Moreover, NLRP3 SNP Q705K is associated with Crohn’s disease, celiac disease and late-onset Alzheimer 
disease17–19. In contrast, OR2B11/NLRP3 SNP rs4353135 and NLRP3 SNP rs6672995 lead to a reduction in 
basal NLRP3 expression and rs6672995 homozygous variant a/a affects IL-1β production. Both SNPs are 
therefore considered to cause a loss of the inflammasome’s function20. So far, knowledge about the role of 
NLRP3 in renal diseases is largely acquired from murine studies, where an important role for both tissue- 
and myeloid-related Nlrp3 in murine IRI was observed8–10. The literature suggests that the pathophysiolog-
ical role of Nlrp3 in murine renal IRI is in part inflammasome-independent8,9,21–23 and might also be related 
to TGF-β signaling24.
We observed an increased risk of rejection with the donor gain-of-function NLRP3 variant Q705K 
(rs35829419) and a reduced risk of rejection in recipients carrying the NLRP3 A71T variant (rs6672995), 
especially within the first year following transplantation. It is known that episodes of acute rejection that 
occur early after transplantation are less detrimental to the graft than those that occur at later time-points. 
Chronic rejection, especially the antibody-mediated variant, is more challenging to treat. Since we observed 
an association of NLRP3 SNPs with early, but not late BPAR, this could explain why we did not identify an 
association with graft loss.
Gene rs number Genotype
Donor Recipient
OR (95% CI) P OR (95% CI) P





































































































Table 2.  Association of NLRP3 single nucleotide polymorphism with delayed graft function, primary non-
function, death-censored graft survival and patient survival. Homozygous dominant (A/A) is considered 
reference group (ref) and compared to heterozygous + homozygous recessive (A/a + a/a), GOF = gain of 
function, LOF = loss of function, OR = odds ratio, CI = confidence interval, HR = hazard ration.
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Little is known about the role of NLRP3 in adaptive immunity. Activation of the NLRP3 inflammasome is 
crucial in IL-1β and IL-18 maturation that in turn, besides their role in innate immunity, play an important 
part in priming of adaptive (allo)immunity. Both cytokines are involved in development and differentiation of 
CD4+ T-helper lymphocytes (reviewed in refs 4 and 25). Nlrp3 is known to boost adaptive immunity in an 
inflammasome-dependent manner in respiratory failure26, but Nlrp3 deficiency does not affect alum-mediated 
adjuvant activity in mice challenged with human serum albumin vaccination27. To date, it is unknown if NLRP3 
is differentially involved in cellular compared to humoral immunity in humans. How gain- and loss-of-function 
variants in the NLRP3 gene affect acute rejection remains speculative and is an area of future study. A limitation 
of our study is the lack of a standardized assays for the determination of donor-specific antibodies over the years 
and we therefore could not investigate whether the association between the NLRP3 variants differed for T cell- 
or antibody-mediated rejection. We were also unable to directly measure the effect of the NLRP3 variants on 
inflammasome-related cytokine production. The current study is the first to describe the association between the 
NLRP3 variants and acute rejection and we therefore acknowledge that other cohort studies should validate the 
generalizability and transportability of our findings.
Interestingly, the association of the NLRP3 gain-of-function specifically in the donor and NLRP3 
loss-of-function specifically in the recipient with the development of rejection suggests that NLRP3 could be 
a double-edged sword in renal transplantation. NLPR3 is known to be expressed in human myeloid and lym-
phoid cells, but also in cells of the renal parenchyma, including tubular epithelial cells9,11,28,29. Tubular epithe-
lial cells express NLRP3, IL-1β and IL-18 and a gain-of-function of NLRP3 could result in elevated levels of 
these cytokines leading to (local) chronic inflammation and chronic kidney injury11,13–16,30. Additionally, tubular 
epithelial NLPR3 could also contribute to kidney fibrosis directly. In experimental murine studies for instance, 
tubular epithelial Nlrp3 was involved in epithelial-mesenchymal transmission (EMT) via TGF-β signaling, which 
is believed to precede the development of interstitial fibrosis and tubular atrophy11. However, besides parenchy-
mal cells, one should keep in mind that also immune cells like resident dendritic cells of donor origin are being 
transplanted and subsequently present alloimmune epitopes in draining lymph nodes and a gain-of-function of 
NLRP3 in these cells could enhance direct allorecognition, resulting in early rejection. NLRP3 loss-of-function 
in recipients on the other hand could alter IL-1β , IL-18 and IL-33 production by (infiltrating) leukocytes upon 
activation, which was shown to be the case for IL-1β 20. This could lead to a dampened alloimmune response after 
transplantation. Further experimental studies are required to determine how NLRP3 is involved in alloimmune 
recognition.
Given the important role of Nlrp3 in murine models of IRI, one would expect a role for the human NLRP3 
gene in delayed graft function. However, neither donor nor recipient NLRP3 SNPs associated with delayed graft 
function or primary nonfunction. This lack of association could be explained by several aspects. Although murine 
ischemia-reperfusion injury is also characterized by tubular necrosis, there are some distinct differences with 
delayed graft function, including differences in circulating leukocyte composition, a slightly different renal anat-
omy, hemodynamic response and the lack of immunosuppressive drugs in the murine IRI model, making a direct 
extrapolation of murine data to the human clinical setting not always possible31. In addition, delayed graft func-
tion is a clinical term describing the need for additional renal replacement therapy, which could have other causes 
Gene rs number Genotype
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Table 3.  Association of NLRP3 single nucleotide polymorphism with biopsy proven acute rejection. 
Homozygous dominant (A/A) is considered reference group (ref) and compared to heterozygous + homozygous 
recessive (A/a + a/a). GOF = gain of function, LOF = loss of function, HR = hazard risk, CI = confidence interval.
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besides IRI-related acute kidney injury rejection, drug toxicity and hyperkalemia32 making it a heterogeneous 
surrogate end-point.
In our study, we grouped A/a and a/a genotype together based on low numbers of the latter group but we do 
not know if A/a is phenotypically different from a/a and how it would affect our study. In donors, we did identify 
patients with a homozygous recessive rs35829419 variant. For this variant, Verma et al. showed that in vitro, the 
rs35829419 mutant monocytes had a significantly higher level of IL1-beta protein at baseline or after stimulation 
with the pro-pyroptotic substance alum (adjuvant)16. Additionally, Roberts et al. observed that in the homozygous 
recessive allele combination, there was an increased plasma concentration of IL1-beta33. It is difficult to extrap-
olate these results to our the findings in our cohort: (1) there was no heterozygous testing in the in vitro experi-
ments by Verma et al., (2) they observed that the excretion of IL1-beta was only partly rescued by a pan-caspase 
inhibitor, indicating potential non-canonical, pyroptotic signalling in their experiments, (3) both studies meas-
ured the full IL1-beta and IL18 protein and not the active forms that are cleaved by the inflammasome complex. 
The loss of function NLRP3 variant rs6672995 was shown to correlate with the NLRP3 expression on the mRNA 
level34. They did not find an association with plasma concentrations of IL1-beta in patients with this variant. In 
line with this report, Villani et al. found that patients who were homozygous for the rs6672995 variant had a lower 
Figure 1. Kaplan-Meier curves for biopsy-proven acute rejection-free survival in donor and recipient 
NLRP3 single nucleotide polymorphisms. Kaplan-Meier curves for rejection-free survival of (A) donor 
NLRP3 single nucleotide polymorphism (SNP) rs35829419 and (B) recipient NLRP3 SNP rs6672995. The 
homozygous dominant genotypes (A/A) are depicted in blue and the combination of the heterozygous (A/a) 
and homozygous recessive (a/a) genotypes are shown in green. The P-value is calculated by log-rank testing.























A/a + a/a Recipient
a 1.0
0.71 (0.55–0.93) 0.01






















A/a + a/a Recipient
a 1.0
0.67 (0.51–0.89) 0.005
Table 4.  Multivariate regression for the association of NLRP3 single nucleotide polymorphism with biopsy 
proven acute rejection. Homozygous dominant (A/A) is considered reference group (ref) and compared 
to heterozygous + homozygous recessive (A/a + a/a). All models are adjusted for donor age, donation type, 
recipient age, recipient gender, cold ischemia time, number of HLA A/B/DR mismatches between donor and 
recipient prior transplantation, pre-transplant panel reactive antibody%, pre-transplant dialysis time and 
induction therapy with IL2-receptor antagonists. aLight-gray area indicates the multivariable models that 
include both NLRP3 SNP (donor rs35829419 and recipient rs6672995) together with the aforementioned 
parameters. GOF = gain of function, LOF = loss of function, HR = hazard risk, CI = confidence interval.
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production of IL1-beta as compared to heterozygous patients20. Again no active IL1-beta (or other inflammasome 
related cytokines), pyroptosis and in this case no patients with a homozygous dominant variant were analyzed 
and we can therefore not extrapolate these results to our cohort.
In summary, we showed that various gain- and loss-of-function genetic variants in the NLRP3 gene differen-
tially associate with biopsy-proven acute rejection, specifically within the first year after renal transplantation. 
These findings imply a complex role for NLRP3 in early allorecognition and rejection, which makes timing of 
interventions that aim at promoting or reducing NLRP3 inflammasome activity crucial.
Material and Methods
Patient genotyping. Samples were collected from a retrospective cohort as described before35,36. Between 
March 1993 and February 2008, 1271 matching donor and recipient peripheral blood mononuclear cells (PBMCs) 
were obtained from all available patients who underwent kidney transplantation at the University Medical Center 
Groningen, The Netherlands. The exclusion criteria were: cases of re-transplantation, combined kidney/pancreas 
or kidney/liver transplantation, technical problems during surgery, the unavailability of DNA and loss of the 
patients on follow-up (Fig. 2). The institutional ethical review board of the University Medical Center Groningen 
approved the study (METc 2014/077). Written informed consent was obtained from all patients. None of the 
living transplant donors were from a vulnerable population and all living donors provided written informed con-
sent. In case of deceased donation, the donors provided informed consent when they registered their donation 
status and by law, no additional consent was needed. The study was conducted according to the principles of the 
declaration of Helsinki. Non-synonymous NLRP3 SNPs were chosen from NCBI (2010). In addition, we chose 
the NLRP3/OR2B11 rs4353135 SNP, located downstream of NLRP3 and upstream of olfactory receptor gene 
OR2B11, which has previously been shown to influence NLRP3 expression levels20. Genotyping of the selected 
SNPs (Supplementary Table 1) was performed using the Illumina VeraCode GoldenGate Assay kit (Illumina, 
San Diego, CA, USA) according to the manufacturer’s instructions. Genotype clustering and calling were per-
formed using Beadstudio Software (Illumina). The selected SNPs were not in linkage disequilibrium (r2 < 0.10; 
SNP Annotation and Proxy Search, Broad institute).
DNA isolation and quality control. Peripheral blood mononuclear cells were used to acquire donor and 
recipient DNA. DNA samples were validated for DNA concentrations using absorbance at 260 nm with a spectro-
photometer (ND-1000, NanoDrop) and purity was assessed by 260/280 and 260/230 absorbance ratios. In case of 
impurity of the sample, repeated isolation attempts were conducted.
Study end-points. The end-points used in this study were: delayed graft function (DGF, defined as the 
requirement for dialysis within the first week after transplantation), primary non function (PNF, defined as non-
functioning of the allograft from transplantation on), time to the first episode of clinical biopsy-proven acute 
rejection (BPAR), death-censored graft failure (defined as the need for dialysis or re-transplantation) and patient 
mortality.
Statistics. Statistical analyses were performed using R version 2.15.2 for Macintosh (www.r-project.org). 
Two-sided P-values below 0.05 were considered statistically significant. As a routine data quality control, the 
Hardy-Weinberg equilibria for the SNPs were tested. Univariate P-values were subjected to Holm-Bonferroni 
correction for multiple testing. For the association with DGF and PNF, logistic regression models were con-
structed. For the association with BPAR, (rejection-mediated) death-censored graft failure and patient survival, 
time-to-event models were created by Cox proportional hazards regression. Data were considered missing (com-
pletely) at random and we therefore performed complete-case multivariable regression on 1014/1271 (79.8%) 
of patients with complete multivariate data available. To validate the effect of missing values on our multivariate 
models, we reperformed the Cox regression analyses on M = 20 imputed datasets by multiple imputations by 
chained equations (MICE). The imputation results from predictive mean matching were visually checked by 
Kernel density plots. Multivariate Cox models were subjected to 10x internal cross-validation and the decline in 
slope in the validation cohort was considered as an overestimation measure. Kaplan-Meier survival curves were 
Figure 2. Flowchart of the included patients. 
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generated to visualize the association between the genotypes of each SNP in donor and recipient and the time to 
BPAR. Due to the low numbers of patients with homozygous recessive (a/a) variants, we used co-dominant mod-
els in which we compared homozygous dominant (A/A) versus heterozygous + homozygous recessive (A/a + a/a) 
individuals.
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